These results, while limited by their observational nature, report similar outcomes as the ones observed in prospective trials, and indicate that there may be a clinical benefit to switching to mTOR inhibitors after failure with VEFGR-targeted therapies in tRCC. The gene discussed is MTOR; the disease is renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.